Johnson & Johnson Reports Strong Q2 2025 Results Amid Trump Tariff Threats, Raises Full-Year Guidance

According to the Zhicheng Finance APP, Johnson & Johnson (JNJ.US) exceeded Wall Street expectations in its second-quarter performance and raised its full-year guidance, demonstrating confidence in growth amid dual threats of tariffs and drug price reductions facing the pharmaceutical industry.

Financial reports show that Johnson & JohnsonSales for the quarter reached $23.7 billion, surpassing analysts' average estimate of $22.8 billion, with second-quarter non-GAAP earnings per share at $2.77, exceeding market expectations by $0.09.

Johnson & Johnson raises mid-point of 2025 revenue guidance by $2 billion to $93.4 billion; adjusts full-year mid-point of earnings per share guidance upward by $0.25 to a range of $10.80-$10.90.

This impressive report card was released as U.S. President Trump is planning to impose additional tariffs on the pharmaceuticals industry. On Tuesday evening, he indicated that the drug tariffs could be implemented "before the end of the month," starting with a lower initial rate that would gradually increase.

A week ago, Trump told reporters that if pharmaceutical companies do not shift more production capacity to the U.S. within the next 12 to 18 months, they would face tariffs of up to 200%.

Johnson & Johnson CFO Joseph Wolk said in an interview that the gradual imposition of tariffs is actually good news. "It shows that the government understands that biopharmaceutical facilities cannot be built overnight," Wolk said, "As long as this dialogue continues, we believe our situation remains optimistic." During pre-market trading in New York on Wednesday, Johnson & Johnson's stock price once rose by 2.1%.

Before Trump's remarks on Tuesday, Johnson & Johnson had halved its estimated tariff expenditure for this year to $200 million. The figure reflects the tariffs already in effect and does not include potential special tariffs on the pharmaceutical industry in the future.

Challenges Remain

Johnson & Johnson Faces Billion-Dollar Patent Cliff for Its Leading Psoriasis Drug Stelara Amid Generic Competition in Europe and the U.S.; Company Pins Hopes on New Products Like Best-Selling Cancer Drug Darzalex and Immunology Treatment Tremfya to Offset Stelara's Decline. After Federal Judge Rejects Settlement Proposal Over Thousands of Talcum Powder Lawsuits, J&J Also Confronts Uncertain Legal Outlook, Required to Defend Case-by-Case Against Claims Linking Baby Powder to Cancer.

Darzalex's quarterly sales reached $3.54 billion, surpassing expectations, while Tremfya achieved $1.19 billion, also exceeding forecasts. Volker stated that Tremfya, which has been approved for the treatment of inflammatory bowel disease, is expected to reach a peak annual sales of $10 billion.

Medical device business contributes $8.54 billion surpassing expectations, while Stelara, whose core patent expired last year, reports $1.65 billion in quarterly sales falling short of analysts' expectations, signaling that the decline of this "cash cow" may be faster than anticipated.

As the first healthcare company to release its earnings report each quarter, Johnson & Johnson is often regarded as an industry bellwether. Its performance has drawn significant attention amid the potential shadow of tariffs and new policies aimed at lowering drug prices.

The White House also threatened to implement a policy that would force pharmaceutical companies to charge the U.S. government the lowest price offered to patients in other wealthy countries. The May executive order demands that drug companies either voluntarily lower prices or face regulatory measures, while vaguely pushing other nations to increase their reimbursement rates for prescription drugs.

Johnson & Johnson announced in March that it will invest over $55 billion in the U.S. in the next four years, joining the ranks of many pharmaceutical companies that have increased their investments in the U.S. since Trump took office. The company did not disclose specific allocation plans, only stating that the investment will cover production, R&D, and technology investment areas.